Holen Sie sich die Stockscreener-App
433.61
1.47%
-6.45
Handel nachbörslich:
433.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$440.06
Offen:
$437.53
24-Stunden-Volumen:
665.45K
Relative Volume:
0.90
Marktkapitalisierung:
$19.56B
Einnahmen:
$3.08B
Nettoeinkommen (Verlust:
$1.24B
KGV:
16.93
EPS:
25.6108
Netto-Cashflow:
$1.07B
1W Leistung:
-5.08%
1M Leistung:
+7.06%
6M Leistung:
+52.51%
1J Leistung:
+21.43%
1-Tages-Spanne:
$430.80
$442.23
1-Wochen-Bereich:
$430.80
$456.52
52-Wochen-Spanne:
$266.98
$459.48
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
433.61 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
143.46 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.80 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.17 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp. Hits New 52-Week High of $455.26 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $459.48 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $455.00 - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week HighHere's What Happened - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
Polaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
A Look at United Therapeutics (UTHR) Valuation as Tyvaso Shows Breakthrough Results in Late-Stage IPF Trial - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
United Therapeutics rides Tyvaso optimism as IPF trial gains momentum - S&P Global
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighStill a Buy? - MarketBeat
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics COO sells $9.49m in UTHR stock - Investing.com India
Is IPF the Next Big Market Opportunity for United Therapeutics? - Yahoo Finance
UBS maintains United Therapeutics stock Buy rating amid patent litigation - Investing.com India
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics stock price target raised to $580 by UBS on Tyvaso outlook - Investing.com Australia
United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments - Investing.com Australia
United Therapeutics (UTHR): UBS Raises Price Target to $580, Mai - GuruFocus
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments By Investing.com - Investing.com Australia
Will United Therapeutics Corporation (UTH) stock beat international competitionWeekly Trade Review & Reliable Trade Execution Plans - newser.com
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data - Investing.com Canada
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data By Investing.com - Investing.com South Africa
United Therapeutics Corporation $UTHR Holdings Lifted by State of Alaska Department of Revenue - MarketBeat
Why United Therapeutics Corporation (UTH) stock stays undervaluedTrade Ideas & Verified Chart Pattern Trade Signals - newser.com
Analyzing drawdowns of United Therapeutics Corporation with statistical tools2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Chart based analysis of United Therapeutics Corporation trendsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Augustine Asset Management Inc. Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
United Therapeutics Rides Tyvaso Wins To Major Gains - Finimize
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 10 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '25 |
Sale |
448.91 |
4,000 |
1,795,655 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 10 '25 |
Sale |
444.70 |
4,000 |
1,778,788 |
130 |
0.45%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):